- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
Watch Milestone Pharmaceuticals' latest callMilestone Pharmaceuticals (NASDAQ:MIST) Q2 2026 Earnings Call · Replay · Aug 12Read the transcript of Milestone Pharmaceuticals (NASDAQ:MIST) Q2 2026 Earnings CallMilestone Pharmaceuticals Inc. on 6ix
Story so far
- Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
- Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT
- Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia
Earlier from Milestone Pharmaceuticals
- Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
- Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT
- Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia
Later from Milestone Pharmaceuticals
- Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
- Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
- Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
- Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
- Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
Follow Milestone Pharmaceuticals into a list and get an email when it puts out news.
Follow Milestone Pharmaceuticals